Ali Ahmed, senior vice president of biosimilars for Fresenius Kabi USA discusses FDA review of the company’s Stimufend pegfilgrastim biosimilar candidate and the marketing of this product.
In this interview, The Center for Biosimilars® speaks with Ali Ahmed, senior vice president of Biosimilars for Fresenius Kabi USA. Ahmed talks about the prospects for the company’s pegfilgrastim biosimilar candidate (Stimufend, referencing Amgen’s Neulasta).
He also discusses Fresenius Kabi’s planned tocilizumab biosimilar candidate (MSB11456), for which positive results were recently reported. MSB11456, for the treatment of rheumatoid arthritis, would reference Actemra.
The company is awaiting completion of an FDA site inspection to enable the completion of the Stimufend application review. Backlogs at the FDA largely owing to COVID-19 have slowed the process for many manufacturers. “We do know that there’s a shortage of resources and they’re doing the best they can under the circumstances,” Ahmed says. The company is cautiously optimistic about an approval in the near future.
For Fresenius Kabi, launching Stimufend would represent the launch of the company’s biosimilars business and an opportunity to extend Fresenius Kabi’s oncology business in the United States. “We have a very robust portfolio with something on the order of 34 different chemotherapy agents currently on the market,” Ahmed says.
The market for pegfilgrastim products is competitive and prices have declined significantly since the first biosimilars appeared. Ahmed says that Fresenius Kabi hopes to compete by differentiating Stimufend via strong customer relationships and patient support, rather than a lowest-cost strategy.
The company has sized up the European Union market for pegfilgrastim biosimilars, and Ahmed notes a chief difference there vs in the United States is that Amgen’s successful Onpro wearable pegfilgrastim device is not available in Europe currently. This product has a roughly 50% share of the market in the United States, and so the competitive dynamics are very different on one side of the Atlantic vs the other. Ultimately, though, Fresenius Kabi does hope to bring a wearable injector to market, Ahmed says.
When it comes to bringing a tocilizumab product to the US market, Fresenius Kabi could be the first, Ahmed notes.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.